This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
This trial is no longer recruiting — here are similar active trials
Matched by cancer type/biomarker, currently recruiting.
The purpose of this study is to assess the efficacy and safety of pembrolizumab (MK-3475) with or without chemotherapy in combination with vibostolimab (MK-7684), boserolimab (MK-5890), MK-4830, MK-0482, I-DXd, or HER3-DXd in treatment-naïve participants with advanced squamous or non-squamous NSCLC. This study is one of the pembrolizumab substudies being conducted under one pembrolizumab umbrella master protocol (MK-3475-U01/KEYMAKER-U01).
This study will assess the safety and efficacy of avutometinib (VS-6766) in combination with defactinib versus Investigator's choice of treatments (ICT) in subjects with recurrent LGSOC who have progressed on a prior platinum-based therapy.
This is a phase 3, randomized, open-label study of opevesostat compared to alternative abiraterone acetate or enzalutamide in participants with metastatic castration-resistant prostate cancer (mCRPC) with respect to overall survival (OS) in participants with mCRPC previously treated with next-generation hormonal agent (NHA) and taxane-based chemotherapy. It is hypothesized that opevesostat is superior with respect to OS in androgen receptor ligand binding domain (AR LBD) mutation-negative and -positive participants.
The purpose of this study is to evaluate the safety and tolerability of Pumitamig alone or in combination with Ipilimumab in participants with first-line advanced or unresectable Hepatocellular Carcinoma (HCC)
TQB2102 is an antibody-drug conjugate comprised of a humanised antibody against Human Epidermal Growth Factor Receptor 2 (HER2), an enzyme-cleavable linker, and a topoisomerase I inhibitor payload, which combine the ability of antibodies to specifically target tumour cells with the highly potent killing activity of drugs with payloads too toxic for systemic administration. This is a Phase 1/Phase 2 study to evaluate the effectiveness, safety, pharmacokinetics (PK) and anti-drug antibody (ADA) of TQB2102 for injection in subjects with HER2-expressing relapsed/metastatic breast cancer.
Original English text from ClinicalTrials.gov
✓ Qualifies
✗ Disqualifies
Simplified criteria — AI translation
Anhui Pronvincial Cancer Hospital
Hefei, China
Lu'an People's Hospital
Lu'an, China
Cancer Hospital Chinese Academy of Medical Science
Beijing, China
Chongqing University Cancer Hospital
Chongqing, China
Sun Yat-Sen University Cancer Center
Guangzhou, China
Jiangmen Central Hospital
Jiangmen, China
Guangxi Medical University Cancer Hospital
Nanning, China
Harbin Medical University Cancer Hospital
Harbin, China
Hunan Cancer Hospital
Changsha, China
Ganzhou People's Hospital
Ganzhou, China
Jilin Cancer Hospital
Changchun, China
Liaoning Cancer Hospital & Institute
Shenyang, China
The First Hospital of China Medical University
Shenyang, China
Cancer Hospital Affiliated to Shandong First Medical University
Jinan, China
Linyi Cancer Hospital
Linyi, China
The First Affiliated Hospital of Xi'an Jiaotong University School of Medicine
Xi'an, China
Shanxi Cancer Hospital
Taiyuan, China
Suining Central Hospital
Suining, China
Tianjin Medical University Cancer Institute & Hospital
Tianjin, China
Zhejiang Cancer Hospital
Hangzhou, China
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 7/1/2026.
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.
We use Google Analytics to understand how you use our tools and to improve them. We don't collect health data and we don't show ads. You can decline - the site will work exactly the same. Privacy policy